An overview on the impact of viral pathogens on Alzheimer's disease

被引:0
|
作者
Amelimojarad, Melika [1 ]
Amelimojarad, Mandana [1 ]
Cui, Xiaonan [1 ]
机构
[1] Dalian Med Univ, Affiliate Hosp 1, Dept Oncol, Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China
关键词
Alzheimer's disease; BBB; SARS-CoV-2; HSV; Viral pathogens; BLOOD-BRAIN-BARRIER; ENDOTHELIAL-CELLS; MOUSE MODEL; IN-VITRO; MECHANISM; PROTEIN; NEUROINFLAMMATION; EXPRESSION; INFECTION; MICROGLIA;
D O I
10.1016/j.arr.2024.102615
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Alzheimer's disease (AD) is the most common type of dementia which affects over than 60 million cases worldwide with higher incidence in low and middle-income countries by 2030. Based on the multifactorial nature of AD different risk factors are linked to the condition considering the brain's beta-amyloid plaques (A beta) and neurofibrillary tangles (NFTs) as its primary hallmarks. Lately, viral photogenes specially after recent SARS-CoV2 pandemic has gained a lot of attention in promoting the neurodegenerative disorder such as AD based on their capacity to increase the permeability of the blood-brain barrier, dysregulation of immune responses, and the impact on A beta processing and phosphorylation of tau proteins. Therefore, in this review, we summarized the important association of viral pathogens and their mechanism by which they contribute with AD formation and development. An overview of the roles of viral pathogens in AD: According to this figure, viruses can infect neurons directly by modulating the BBB, transferring from endothelial cells to glial cells and then to neurons, increasing the A beta deposition, and affecting the tau protein phosphorylation or indirectly through the virus's entrance and pathogenicity that can be accelerated by genetic and epigenetic factors, as well as chronic neuroinflammation caused by activated microglia and astrocytes.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Mucosal immunotherapy for Alzheimer's disease with viral vectors
    Hara, H.
    Inoue, M.
    Hasegawa, M.
    Yonemitsu, Y.
    Nabeshima, T.
    Tabira, T.
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 178 : 18 - 18
  • [32] Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews
    Majidazar, Reza
    Rezazadeh-Gavgani, Erfan
    Sadigh-Eteghad, Saeed
    Naseri, Amirreza
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (10) : 1567 - 1587
  • [33] The effect of curcumin (turmeric) on Alzheimer's disease: An overview
    Mishra, Shrikant
    Palanivelu, Kalpana
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2008, 11 (01) : 13 - 19
  • [34] Alzheimer's disease: overview, risk factors and prevention
    Rigaud, AS
    Forette, F
    M S-MEDECINE SCIENCES, 2002, 18 (6-7): : 689 - 696
  • [35] An overview of the social and behavioral consequences of Alzheimer's disease
    Pearlin, LI
    Harrington, C
    Lawton, MP
    Montgomery, RJV
    Zarit, SH
    AGING & MENTAL HEALTH, 2001, 5 : S3 - S6
  • [36] Gene Therapy Strategies for Alzheimer's Disease: An Overview
    Alves, Sandro
    Fol, Romain
    Cartier, Nathalie
    HUMAN GENE THERAPY, 2016, 27 (02) : 100 - 107
  • [37] An overview of glutaminyl cyclase inhibitors for Alzheimer's disease
    Coimbra, Judite R. M.
    Sobral, Pedro J. M.
    Santos, Armanda E.
    Moreira, Paula, I
    Salvador, Jorge A. R.
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (24) : 3179 - 3194
  • [38] Lipid Integration in Neurodegeneration: An Overview of Alzheimer's Disease
    Yadav, Rajesh Singh
    Tiwari, Neeraj Kumar
    MOLECULAR NEUROBIOLOGY, 2014, 50 (01) : 168 - 176
  • [39] Ethical issues in Alzheimer's. disease: an overview
    Leuzy, Antoine
    Gauthier, Serge
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2012, 12 (05) : 557 - 567
  • [40] Angiotensins and Alzheimer's disease: a bench to bedside overview
    Kehoe, Patrick G.
    ALZHEIMERS RESEARCH & THERAPY, 2009, 1 (01):